CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 272 enrolled
Drug / intervention
Fish Oil +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00663871
NCT00663871N/ACompleted
CompareCT.gov

BioBehavioral Studies of Cardiovascular Disease

University of Pittsburgh·interventional·Posted Apr 22, 2008·Updated Jun 11, 2021

In Brief

A clinical study evaluating Fish Oil and Soybean Oil (Placebo) for Cardiovascular Diseases and 2 related conditions. Completed, enrolled 272 participants across 1 site.

Detailed Summary

Omega-3 fatty acids are a certain kind of fish fat that has recently been shown to have health benefits. This study will examine the effectiveness of fish oil supplementation for reducing the early signs of heart disease risk and for improving mood, impulsivity, and anger levels.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Diseases, Mood Disorders, Inflammation
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), National Center for Complementary and Integrative Health (NCCIH), Office of Dietary Supplements (ODS)

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 22, 2008
Enrollment StartJun 1, 2008
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 18.2 years ago

Interventions

Fish Oildietary

Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.

Soybean Oil (Placebo)dietary

Participants will take 2 grams of soybean oil supplements on a daily basis.